Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

NCT05186558 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type

Interventions

DRUG: penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

Sponsor

The First Affiliated Hospital with Nanjing Medical University